



Australian Government
Department of Health
 Therapeutic Goods Administration

Public Summary

| | | |
|--------------------------------|--|---------------|
| Summary for ARTG Entry: | 351927 | Opti Active D |
| ARTG entry for | Medicine Listed | |
| Sponsor | Factors Group Australia Pty Ltd | |
| Postal Address | Unit B 10-16 South Street, Rydalmere, NSW, 2116 Australia | |
| ARTG Start Date | 18/12/2020 | |
| Product Category | Medicine | |
| Status | Active | |
| Approval Area | Listed Medicines | |

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Opti Active D

| | | | |
|---------------------|-------------------------|-----------------------|-----------|
| Product Type | Single Medicine Product | Effective Date | 8/02/2021 |
|---------------------|-------------------------|-----------------------|-----------|

Permitted Indications

- Maintain/support healthy teeth
- Maintain/support bone health
- Maintain/support bone health in post-menopausal women
- Aids/assists healthy bone development/growth/building
- Maintain/support bone mass/density/integrity
- Maintain/support bone mass/density/integrity in post-menopausal women
- Maintain/support bone strength
- Maintain/support bone strength in post-menopausal women
- Help maintain/support bone mineralisation
- Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life
- Maintain/support immune system health
- Enhance/improve/promote immune defence/immunity
- Maintain/support healthy immune system function
- Maintain/support immune system to fight illness
- Enhance/improve/promote/increase (state vitamin/mineral/nutrient) levels in the body
- Maintain/support (state vitamin/mineral/nutrient) levels in the body
- Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
- Maintains/support healthy foetal development
- Maintain/support healthy pregnancy

Indication Requirements

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Label statement: Advise your doctor of any medicine you take during pregnancy, particularly in your first trimester.

Indication only for use for medicines that contain vitamin D as an active ingredient. The medicines may only contain a maximum recommended daily dose

Public Summary



Australian Government
Department of Health
 Therapeutic Goods Administration

of 25 micrograms or less of vitamin D and as a minimum, also contain at least 25% of the RDI in the recommended daily dose of vitamin D.

Product presentation must not imply or refer to serious immunological diseases.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

The medicine should not be taken in combination with supplements containing Vitamin D without medical advice (or words to that effect). Calcifediol may have similar effects to Vitamin D. Consult your health care professional before taking in combination with other medicines. Use in children under 9 years is not recommended.

Additional Product information

Pack Size/Poison information

| | |
|------------------|------------------------|
| Pack Size | Poison Schedule |
|------------------|------------------------|

Components

1 . Formulation 1

| | |
|--------------------------------|------------------|
| Dosage Form | Tablet, uncoated |
| Route of Administration | Oral |

Visual Identification

Active Ingredients

| | |
|-------------------------|--------|
| calcifediol monohydrate | .01 mg |
|-------------------------|--------|

Other Ingredients (Excipients)

- calcium hydrogen phosphate dihydrate
- croscarmellose sodium
- crospovidone
- dl-alpha-tocopherol
- magnesium stearate
- medium chain triglycerides
- microcrystalline cellulose
- silicon dioxide
- sodium ascorbate
- starch sodium octenyl succinate
- sucrose

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.